[EN] USE OF CERITINIB (LDK-378) IN THE TREATMENT OF FES OR FER MEDIATED DISORDERS, IN PARTICULAR PROLIFERATIVE DISORDERS [FR] UTILISATION DU CÉRITINIB (LDK -378) DANS LE TRAITEMENT DE TROUBLES MÉDIÉS PAR FES OU FER, EN PARTICULIER DES TROUBLES PROLIFÉRATIFS
[EN] COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME<br/>[FR] COMPOSÉS UTILES POUR STIMULER LA DÉGRADATION DES PROTÉINES ET PROCÉDÉS UTILISANT CEUX-CI
申请人:UNIV YALE
公开号:WO2013170147A1
公开(公告)日:2013-11-14
The present invention includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In one embodiment, the invention comprises a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. The target protein contemplated within the invention comprises a posttranslational modified protein or intracellular protein. Compounds of the present invention may be used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.
Compounds Useful for Promoting Protein Degradation and Methods Using Same
申请人:Yale University
公开号:US20160022642A1
公开(公告)日:2016-01-28
The present description includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the description includes a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. The target protein contemplated within the description comprises an androgen receptor. Compounds of the present description may be used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.
A convergent and high-yielding approach for the asymmetricsynthesis of sulforaphane 2 and four analogues differently substituted at the sulfinyl sulfur has been developed. The key step of the synthesis is the diastereoselectivesynthesis of sulfinate ester 23-SS, using the DAG (diacetone-d-glucofuranose)-methodology. The biological activity of these compounds as inductors of phase II detoxifying enzyme
已开发出一种收敛性和高产率的方法,用于不对称合成萝卜硫烷2和在亚磺酰基硫上被不同取代的四个类似物。合成的关键步骤是亚磺酸酯的非对映合成23 -小号小号,使用DAG(diacetone- d -glucofuranose)-methodology。通过确定它们激活细胞保护性转录因子Nrf2的能力,研究了这些化合物作为II期解毒酶诱导剂的生物活性。
[EN] CLICK-MASS SPECTROMETRY OF ALKYNE-LABELED COMPOUNDS<br/>[FR] SPECTROMÉTRIE DE MASSE PAR CLIC DE COMPOSÉS MARQUÉS PAR ALCYNE
申请人:UNIV BONN RHEINISCHE FRIEDRICH WILHELMS
公开号:WO2020002634A1
公开(公告)日:2020-01-02
The present invention relates to specific nitrogen containing compounds of formulas (I), (II) and (IV) of the present invention, which are suitable to be used in a method to detect alkyne group containing organic compounds by mass spectrometry. Furthermore, the present invention relates to methods for the synthesis of these compounds and for the detection of organic compounds containing the specific compounds of the present invention, uses of the compounds in mass spectrometry, for determining enzyme activity or monitoring the lipid metabolism in a cell, and a kit, which contains at least one of these compounds and at least one internal standard.
COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME
申请人:YALE UNIVERSITY
公开号:US20150119435A1
公开(公告)日:2015-04-30
The present invention includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the invention comprises a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. In other embodiments, the target protein contemplated within the invention comprises a posttranslational modified protein or intracellular protein. In yet other embodiments, compounds of the present invention are used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.